Skip to main
CODX
CODX logo

Co-Diagnostics (CODX) Stock Forecast & Price Target

Co-Diagnostics (CODX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Co-Diagnostics Inc is positioned positively due to its innovative proprietary technologies that simplify and reduce the cost of molecular diagnostics, particularly through the development of a new sample preparation instrument for point-of-care PCR testing. The company's strategic international presence, including joint ventures and manufacturing capabilities, enhances its potential to scale operations and expand access to affordable diagnostics in underserved regions. Additionally, ongoing advancements in regulatory pathways for the Co-Dx PCR platform and the company's commitment to addressing broader diagnostic challenges indicate a strong foundational support for future growth opportunities.

Bears say

Co-Diagnostics Inc. is facing a negative outlook primarily due to a significant reduction in its projected price target, which has declined from $10.00 to $3.00 based on revised assumptions regarding its financial performance. With a cash balance of $11 million, the company is projected to incur quarterly expenses of $5-7 million, which raises concerns about its financial sustainability and suggests that upcoming capital raises may lead to further dilution and unfavorable terms. Additionally, trading below $1.00 adds pressure to the company’s ability to secure necessary financing, potentially leading to a downward financing spiral that could further harm its market valuation.

Co-Diagnostics (CODX) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Co-Diagnostics (CODX) Forecast

Analysts have given Co-Diagnostics (CODX) a Buy based on their latest research and market trends.

According to 3 analysts, Co-Diagnostics (CODX) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Co-Diagnostics (CODX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.